POC
POC is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at POC.
POC is a company.
Key people at POC.
Key people at POC.
PoC Capital, LLC is a single-family office based in Woodside, California, founded in 2015 by biotech executive Daron Evans.[1] It manages family capital from Evans' roles in public and private life-science enterprises, focusing exclusively on micro- and small-cap public life science companies by providing proof-of-concept (PoC) funding for clinical trials in exchange for equity and warrants.[1][2] The firm's mission centers on investing in product candidates that improve patient well-being, prioritizing strong management, clear mechanisms of action, and validated development plans to unlock asset value through safety and efficacy data.[2] In the startup ecosystem, PoC Capital bridges critical funding gaps for emerging therapeutics developers, enabling pivotal clinical validation that often attracts larger follow-on investments.[1]
PoC Capital traces its roots to 2015, when Daron Evans, a seasoned biotech executive, established it as the Evans Family Office in Woodside, CA.[1] Evans built his expertise through leadership, investment, and advisory positions across life-science firms, generating the family capital that fuels the office's direct investments.[1] The firm's focus evolved to target proof-of-concept clinical trials for small public companies, a niche honed from Evans' deep industry experience in therapeutics development.[1][2] This hands-on approach reflects a pivot from broader biotech involvement to specialized, high-impact PoC funding that de-risks early-stage assets.[2]
PoC Capital rides the wave of precision medicine and biotech derisking, where proof-of-concept trials are essential to validate novel therapeutics amid rising R&D costs and investor scrutiny.[2] Timing is ideal in a market favoring public micro-caps, as smaller firms struggle with trial funding post-seed but pre-Series A, amplified by post-pandemic biotech funding droughts.[1] Favorable forces include regulatory pushes for faster approvals (e.g., FDA breakthroughs) and demand for patient-centric innovations, positioning PoC Capital to catalyze ecosystem growth by enabling trial data that draws institutional capital.[2] It influences the landscape by sustaining small innovators, fostering a pipeline of viable assets that larger pharma can acquire or partner with.
PoC Capital is primed to expand its niche as biotech rebounds, with AI-driven trial design and personalized therapies amplifying PoC's value in accelerating validation.[2] Upcoming trends like modular trials and real-world evidence will shape its portfolio, potentially evolving toward hybrid public-private deals amid volatile markets. Its influence may grow by mentoring more first-time biotech leaders, solidifying Evans' model as a blueprint for family-office impact—ultimately fueling patient breakthroughs from overlooked small-caps.[1][2]
